IMU 1.89% 5.2¢ imugene limited

Ann: Phase 1 onCARlytics Trial Advances to Combination Arm, page-9

  1. 2,882 Posts.
    lightbulb Created with Sketch. 12220
    Hi GMT2!

    Yes - more good news. Expected - but still good to hear.

    I also find it interesting that IMU mentions Gilead's Yescarta. They used similar wording back in October. Gilead has been pushing hard in the CAR-T space and sees it as the future. They paid a shirt load to buy Kite Pharma, who developed Yescarta. $11.9b USD, I believe.

    You would have to think that Gilead has been watching OnCARlytics with considerable interest. For that matter - also Azer-Cel.

    Cheers

    Dave



 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.